PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- GSK to Seek COPD Indication for Relvar in January-March 2016
October 6, 2015
- Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
- Japan OTC Drug Market Logs 1st Rise in 5 Years: Fuji Keizai
October 5, 2015
- Mitsubishi Tanabe Wins Rights to Regeneron’s NGF Antibody in Asia
October 5, 2015
- Otsuka Files Combination Glaucoma Eye Drops in Japan
October 2, 2015
- ASKA Takes Over 2 Anti-Thyroid Drugs from Chugai
October 2, 2015
- Active Promotion of HPV Vaccines Should Be Resumed: GSK
October 1, 2015
- Mitsubishi Tanabe Raises Full-Year Earnings Projection
October 1, 2015
- Nichi-Iko Files Remicade Biosimilar in Japan
October 1, 2015
- Sato, POLA to Jointly Market Clenafin Competitor Drug
October 1, 2015
- Eisai Ups April-Sept. Profit Forecasts on Lower Sales
October 1, 2015
- Asahi Kasei Pharma Seek Japan Approval of Once-Yearly Osteoporosis Drug
October 1, 2015
- Astellas Licenses Analgesic Ion Channel Blocker from US Chromocell
October 1, 2015
- Fujifilm to Establish Cellular Dynamics Japan for iPS Biz
September 30, 2015
- CMIC Holdings CEO to Double as OrphanPacific Chairman
September 30, 2015
- Halaven Now under FDA’s Priority Review for Soft Tissue Sarcoma: Eisai
September 30, 2015
- Janssen Seeks Pediatric Use for Ultiva in Japan
September 30, 2015
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
- GSK to Compensate for Add’l Patient Burdens Tied to Hep B Drug Shortage
September 29, 2015
- Takeda Files Nesina-Metformin Combo Drug in Japan
September 29, 2015
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…